Survival outcomes from the CALGB 40603 study in triple-negative breast cancer

Dr. Charles Perou | Distinguished Lectureship in Breast Cancer Research | SABCS 2022Подробнее

Estimating Outcomes in Triple Negative Breast CancerПодробнее

William M SikovПодробнее

Treatment advances in TNBCПодробнее

Triple-negative breast cancer: Adding carboplatin to presurgery chemotherapy improved survivalПодробнее

Real-World Outcomes Among Patients With Metastatic Triple-Negative Breast CancerПодробнее

Dr. William Sikov on Triple-Negative Breast Cancer Patients Not Responding to TreatmentПодробнее

Dr. Arteaga Discusses the CALGB 40603 TrialПодробнее

Association of pathologic complete response following neoadjuvant chemotherapy with longterm sur...Подробнее

Triple-Negative Breast CancerПодробнее

Tackling residual disease in breast cancerПодробнее

Neoadjuvant and adjuvant therapy in triple negative breast cancerПодробнее

CALGB 40601 Alliance: impact of dual HER2 targeting on pCRПодробнее

SABCS2014: CALGB 40603/150709 (Alliance): William M. SikovПодробнее

What to Know about Triple Negative Breast CancerПодробнее

Value of Circulating Tumor DNA After Neoadjuvant Chemotherapy for Triple Negative Breast CancerПодробнее

Latest Advances in Triple-Negative Breast Cancer Treatment and CareПодробнее

Current treatment landscape of triple negative breast cancerПодробнее

Dr. Eric Winer on Carboplatin and/or Bevacizumab in Triple-Negative Breast CancerПодробнее